Hørsholm, September 23, 2013
Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people with diabetes and obesity. The new research program initiated between Gubra and Sanofi builds upon the established research consortium between Gubra, Gentofte Hospital and the University of Copenhagen partly funded by the Danish National Advanced Technology foundation.
“We are delighted at the prospect of working with the Gubra target discovery team on this particular project,” said Philip Just Larsen, Head of Research and Translational Medicine of the Global Diabetes Division at Sanofi. “And we hope that this project which utilizes the comprehensive Gubra expertise in molecular pathways will open the door to the development of new treatments for patients with type 2 diabetes,” he added.
Niels Vrang, CEO at Gubra emphasized the importance of the research collaboration between Gubra and Sanofi: “This alliance will facilitate the development of new targets and new drugs and we are really happy that Sanofi realized the synergistic potential in our established research collaboration with Gentofte Hospital (Diabetes Research Division, Filip K. Knop) and University of Copenhagen (Department of Chemistry, Knud J. Jensen)”. In 2012 Gubra, Gentofte and University of Copenhagen received partial funding from the Danish National Advanced Technology Foundation for a target/drug discovery project focusing on novel gut peptides.
Under the terms of the agreement, Sanofi will provide Gubra research funding over the course of the collaboration. If certain developments, regulatory and commercial milestones are achieved, Gubra and their research partners will be entitled to receive payments, as well as royalties on worldwide product sales.
Sofia Pitt Boserup
Lead Communication Partner
Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra’s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at www.gubra.dk
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, business dealings, product development and potential, services as well as statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties. Many of these risks and uncertainties are difficult to predict and are in principle beyond the control of Sanofi and could cause actual results and developments to differ considerably from those expressed in or implied or projected by the forward-looking information and statements. These risks and uncertainties include, among other things, the following: uncertainties inherent in research and development, future clinical data and analyses, including post marketing; decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, medical device or biological application that may be filed for any such product candidates; decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates; the absence of guarantee that the product candidates, if approved, will be commercially successful; the future approval and commercial success of therapeutic alternatives as well as the risks and uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward Looking Statements“ in Sanofi’s annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.